Sensidose recently reported an increase in net sales of 21 per cent for the second quarter compared to the same period in 2021. At the same time as the company is growing, they have also made progress during the quarter in the development of the new dosing device, which is expected to drive further growth and profitability in the coming years. The company is now looking forward to the coming months when several pieces of the puzzle are expected to fall into place, according to CEO Jack Spira.
Biostock: Continued positive sales development for Sensidose
Aug 26, 2022